Prime Medicine, Inc.

Prime Medicine, Inc. reported its Q2 2026 financial results, highlighting a significant going concern warning from management, indicating substantial doubt about the company's ability to continue operations for the next 12 months. The biotechnology company posted a net loss of $(42.1) million for the quarter, an improvement from the prior year, but its cash and short-term investments stood at $95.1 million, with an accumulated deficit nearing $980 million. Total assets and stockholders' equity also saw notable declines compared to year-end 2025.

Prime Medicine reported a net loss of $42.1 million for Q2 2026, an improvement from $52.6 million in Q2 2025, with R&D and G&A expenses decreasing. The company announced significant clinical progress, including IND and CTA clearances for PM577a in Wilson disease, establishing a global Phase 1/2 program. They also secured rights to PM647 in Alpha-1 Antitrypsin Deficiency following a favorable arbitration and received FDA Regenerative Medicine Advanced Therapy (RMAT) designation for PM359, with a BLA submission planned for 1H 2027. Prime Medicine ended the quarter with $108.8 million in cash, providing a runway into 2027.

Prime Medicine announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for PM577a, an investigational in vivo Prime Editor for Wilson disease. This clearance, combined with a previously cleared New Zealand Clinical Trial Application (CTA), establishes a global Phase 1/2 clinical program. PM577a targets the H1069Q mutation in the ATP7B gene, which is the most prevalent WD-causing allele in North America and Europe. The company expects to initiate the Phase 1/2 trial in the second half of 2026, with initial clinical data anticipated in 2027.

Prime Medicine, Inc. announced it received a final arbitration award on July 6, 2026, in its dispute with Beam Therapeutics, Inc. The Tribunal declared that Prime Medicine's development candidate, PM647 for Alpha-1 Antitrypsin Deficiency, falls within its defined "Field" under their 2019 Collaboration and License Agreement, confirming no breach by Prime Medicine. Consequently, Beam's requests for damages and injunctive relief were denied, and all other claims from both parties were also denied.

Prime Medicine, Inc. announced that the New Zealand Medicines and Medical Devices Safety Authority (Medsafe) has cleared its Clinical Trial Application (CTA) for PM577a, an investigational Prime Editor for Wilson Disease. This represents the company's first clinical authorization for an in vivo Prime Editing therapy. Prime Medicine expects to initiate a global Phase 1/2 clinical trial in the second half of 2026, with initial clinical data anticipated in 2027. PM577a targets the H1069Q mutation, the most prevalent Wilson Disease-causing allele in North America and Europe, with plans for additional products to address other pathogenic variants globally.

Prime Medicine, Inc. announced that its Chief Executive Officer, Allan Reine, M.D., will participate in a fireside chat at the Jefferies Global Healthcare Conference. The event is scheduled for Thursday, June 4, 2026, at 12:50 p.m. ET in New York, NY. A live audio webcast and a 90-day replay will be available on the company's website.

Prime Medicine reported a net loss of $49.1 million for the first quarter of 2026, an improvement from $51.9 million in the prior year. However, the company's management has concluded that substantial doubt exists about its ability to continue as a going concern for the next 12 months, citing dependence on obtaining additional financing. As of March 31, 2026, the company held $135.5 million in cash, cash equivalents, and short-term investments, with an accumulated deficit of $937.5 million.

Prime Medicine reported a Q1 2026 net loss of $49.1 million, an improvement from $51.9 million in Q1 2025. The company announced pipeline progress, including being on track to file IND/CTA for PM577 and PM647 in H1 and mid-2026, respectively, with initial clinical data expected in 2027. Additionally, Svetlana Makhni was appointed as Chief Financial Officer in April 2026, and the company maintains a cash runway into 2027 with $149.2 million in cash and investments.

Prime Medicine, Inc. reported its first-quarter 2026 financial results and provided a business update, highlighting significant pipeline progress. The company remains on track to file IND/CTA applications for PM577 in Wilson Disease in H1 2026 and PM647 in AATD mid-2026, with initial clinical data from both programs anticipated in 2027. Prime Medicine also announced the appointment of Svetlana Makhni as Chief Financial Officer and reported a cash position of $149.2 million as of March 31, 2026, providing a cash runway into 2027.

Prime Medicine, Inc. has appointed Svetlana Makhni as its new Chief Financial Officer, effective April 16, 2026. Ms. Makhni will report to the Chief Executive Officer and will be based in Cambridge, Massachusetts. Her compensation package includes an annual base salary of $495,000 and eligibility for an annual target performance bonus of 40% of her base salary.